$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000144702824000087 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$1.339M
YoY Change		-71.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.537M
YoY Change		-22.31%
% of Gross Profit
Research & Development		$14.27M
YoY Change		-29.23%
% of Gross Profit
Depreciation & Amortization		$336.0K
YoY Change		-9.19%
% of Gross Profit
Operating Expenses		$22.78M
YoY Change		-13.11%
Operating Profit		-$21.44M
YoY Change		-0.55%
Interest Expense		$1.723M
YoY Change		3645.65%
% of Operating Profit
Other Income/Expense, Net		$1.723M
YoY Change		18.5%
Pretax Income		-$19.72M
YoY Change		-1.92%
Income Tax
% Of Pretax Income
Net Earnings		-$19.72M
YoY Change		-1.92%
Net Earnings / Revenue		-1472.52%
Basic Earnings Per Share		-$0.10
Diluted Earnings Per Share		-$0.10
COMMON SHARES
Basic Shares Outstanding	189.5M shares	188.8M shares
Diluted Shares Outstanding		189.0M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$127.8M
YoY Change		-4.76%
Cash & Equivalents		$31.85M
Short-Term Investments		$95.95M
Other Short-Term Assets		$3.375M
YoY Change		-36.32%
Inventory
Prepaid Expenses
Receivables		$1.608M
Other Receivables		$0.00
Total Short-Term Assets		$132.8M
YoY Change		-6.24%
LONG-TERM ASSETS
Property, Plant & Equipment		$3.556M
YoY Change		-29.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$7.664M
YoY Change		-55.01%
TOTAL ASSETS
Total Short-Term Assets		$132.8M
Total Long-Term Assets		$7.664M
Total Assets		$140.4M
YoY Change		-11.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.880M
YoY Change		25.22%
Accrued Expenses		$5.132M
YoY Change		-35.85%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$18.92M
YoY Change		-15.23%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$14.63M
YoY Change		-13.95%
Total Long-Term Liabilities		$14.63M
YoY Change		-13.95%
TOTAL LIABILITIES
Total Short-Term Liabilities		$18.92M
Total Long-Term Liabilities		$14.63M
Total Liabilities		$33.55M
YoY Change		-14.64%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.334B
YoY Change		6.1%
Common Stock		$1.408B
YoY Change		4.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$106.9M
YoY Change
Total Liabilities & Shareholders Equity		$140.4M
YoY Change		-11.47%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$19.72M
YoY Change		-1.92%
Depreciation, Depletion And Amortization		$336.0K
YoY Change		-9.19%
Cash From Operating Activities		-$20.74M
YoY Change		-4.79%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		-$11.99M
YoY Change		-214.59%
Cash From Investing Activities		-$11.99M
YoY Change		-214.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.775M
YoY Change		5.65%
NET CHANGE
Cash From Operating Activities		-20.74M
Cash From Investing Activities		-11.99M
Cash From Financing Activities		1.775M
Net Change In Cash		-30.95M
YoY Change		220.03%
FREE CASH FLOW
Cash From Operating Activities		-$20.74M
Capital Expenditures		$0.00
Free Cash Flow		-$20.74M
YoY Change		-4.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34949
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
	dei	Security12b Title Security12bTitle	Common Shares, without par value
	dei	Trading Symbol TradingSymbol	ABUS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	189491685	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31846000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1776000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3375000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4248000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	132777000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	132027000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12663000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11900000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3556000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4674000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	6284000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1144000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1416000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	22779000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	26216000	usd
	us-gaap	Operating Expenses OperatingExpenses	66983000	usd
	us-gaap	Operating Expenses OperatingExpenses	73352000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21558000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-62386000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57356000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1747000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1494000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5121000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4223000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	11000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1723000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1454000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4998000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3819000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	ARBUTUS BIOPHARMA CORP
	dei	City Area Code CityAreaCode	267
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	2964000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21440000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-16000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	218000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-19717000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	106890000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2131000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26285000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95948000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	99718000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1608000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7544000	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10911000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	11791000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	468000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	425000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18923000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22487000	usd
CY2024Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	5315000	usd
CY2023Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	6953000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8335000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7600000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	978000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1343000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	33551000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38383000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38383000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38383000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169867414	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169867414	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1407595000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1349821000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1334040000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1276652000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48090000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48421000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	106890000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	106018000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140441000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	144401000	usd
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	us-gaap	Assets Assets	140441000	usd
CY2023Q4	us-gaap	Assets Assets	144401000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10271000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189438135	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189438135	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81425000	usd
CY2024Q3	us-gaap	Revenues Revenues	1339000	usd
CY2023Q3	us-gaap	Revenues Revenues	4658000	usd
	us-gaap	Revenues Revenues	4597000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14273000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20169000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45227000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56136000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4537000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5842000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17396000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17374000	usd
CY2024Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	344000	usd
CY2023Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	205000	usd
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	735000	usd
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-158000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188997194	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81270000	usd
	us-gaap	Revenues Revenues	15996000	usd
CY2024Q3	us-gaap	Restructuring Charges RestructuringCharges	3625000	usd
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	3625000	usd
	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	29000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	46000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	107000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	415000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-19717000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20104000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57388000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53537000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188997194	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167512708	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	167512708	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	184244819	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	165085243	shares
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	218000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	584000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	331000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	1604000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19499000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19520000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57057000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51933000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	106018000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2014000	usd
CY2024Q1	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	21765000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2454000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	211000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	50000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-17875000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	114637000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3180000	usd
CY2024Q2	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	22359000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2011000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	63000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-19796000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	122454000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2160000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1590000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	185000	usd
CY2023Q1	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	19862000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	259000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	296000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	854000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16339000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	143915000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2964000	usd
CY2023Q2	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	4742000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	166000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17094000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	134693000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2483000	usd
CY2023Q3	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	1396000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	285000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	584000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20104000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	119337000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57388000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53537000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1047000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1045000	usd
	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	167000	usd
	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7354000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7578000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	735000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-158000	usd
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	1736000	usd
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	2667000	usd
	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	98000	usd
	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	412000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2212000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1577000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-168000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	819000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1145000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2040000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2727000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6223000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-880000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10349000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-306000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-289000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54535000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68644000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	98318000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	56490000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	107951000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	86026000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1008000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9537000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28548000	usd
	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	44124000	usd
	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	26000000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6055000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	259000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	396000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	581000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50575000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26840000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-16000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5561000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13245000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26285000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30776000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31846000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17531000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of business and future operations</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (“Arbutus” or “the Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. The Company believes the key to success in developing a functional cure involves suppressing hepatitis B virus deoxyribonucleic acid, reducing hepatitis B surface antigen and boosting HBV-specific immune responses. The Company’s pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to protect and defend its intellectual property, which is the subject of the Company’s ongoing lawsuits against Moderna Therapeutics, Inc. (Moderna) and Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of the Company’s patented lipid nanoparticle (LNP) technology in their COVID-19 vaccines. With respect to the Moderna lawsuit, the claim construction hearing occurred on February 8, 2024. On April 3, 2024, the court provided its claim construction ruling in which it construed the disputed claim terms and agreed with the Company’s position on most of the disputed claim terms. On August 5, 2024, the Company and Genevant Sciences Ltd. (Genevant), along with Moderna, filed a Stipulation to Extend Time with the court that requested an amended case schedule to accommodate certain outstanding discovery from Moderna and third parties. The court approved the amended case schedule and the start of the trial was moved from April 21, 2025 to September 24, 2025, subject to the court’s availability. The lawsuit against Pfizer/BioNTech is ongoing and a date for a claim construction hearing has been scheduled for December 18, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, the Company had an aggregate of $130.8 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of September 30, 2024. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div>
CY2024Q3	us-gaap	Investments And Cash InvestmentsAndCash	130800000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2024Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	1	subsidiary
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21000000.0	shares
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8300000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	700000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7600000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	735000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8335000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-158000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7373000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	2932000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	2964000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	6273000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	6284000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	7	numberofsegments
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	27	numberofsegments
CY2024Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	300000	usd
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	300000	usd
CY2024Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2024Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2315000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3223000	usd
CY2024Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	1367000	usd
CY2023Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2884000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	709000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	815000	usd
CY2024Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	2588000	usd
CY2023Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3349000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	565000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	0	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7544000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10271000	usd
CY2023Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	6953000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	1736000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	2667000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Interest Expense LiabilityFromSaleOfFutureRoyaltiesNonCashInterestExpense	98000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Interest Expense LiabilityFromSaleOfFutureRoyaltiesNonCashInterestExpense	412000	usd
CY2024Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	5315000	usd
CY2023Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	8110000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	10911000	usd
CY2024Q3	abus	Royalty Entitlements RoyaltyEntitlements	2	product
CY2024Q3	us-gaap	Revenues Revenues	1339000	usd
CY2023Q3	us-gaap	Revenues Revenues	4658000	usd
	us-gaap	Revenues Revenues	4597000	usd
	us-gaap	Revenues Revenues	15996000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.25
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.78
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1316200	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1344550	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.40
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.90
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2160000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2483000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7354000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7578000	usd
CY2024Q3	us-gaap	Restructuring Reserve RestructuringReserve	600000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001447028-24-000087-index-headers.html	Edgar Link	pending
0001447028-24-000087-index.html	Edgar Link	pending
0001447028-24-000087.txt	Edgar Link	pending
0001447028-24-000087-xbrl.zip	Edgar Link	pending
a2024-q310xqex311.htm	Edgar Link	pending
a2024-q310xqex312.htm	Edgar Link	pending
a2024-q310xqex321.htm	Edgar Link	pending
a2024-q310xqex322.htm	Edgar Link	pending
abus-20240930.htm	Edgar Link	pending
abus-20240930.xsd	Edgar Link	pending
abus-20240930_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
abus-20240930_cal.xml	Edgar Link	unprocessable
abus-20240930_def.xml	Edgar Link	unprocessable
abus-20240930_lab.xml	Edgar Link	unprocessable
abus-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abus-20240930_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2024 Q4 Form 10-Q Financial Statement

#000144702824000087 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2024 Q4 Form 10-Q Financial Statement

#000144702824000087 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus